PepSavvySearch peptides

Search peptides

Popular peptides
↑ ↓ Navigate ↵ OpenBrowse all peptides
Saved0
All peptidesTB-500
Recovery

TB-500

Thymosin beta-4 fragment

Lab studiesTissue-repair mechanisms1
Community reportsInjury recovery4

No FDA-approved TB-500 product; fragment identity must be distinguished from full-length Tβ4.

What does it do?

Marketed TB-500 commonly denotes a thymosin-beta-4 fragment; full-length Tβ4 findings cannot automatically be assigned to it.

Approved & studied uses

Fragment research

1

Analytical research verified the acetylated seven-residue fragment in a veterinary product.

Community uses Reported, unvalidated

Repair

12

Muscle, tendon, ligament, wound and exercise-recovery claims.

Neural

12

Brain/spinal injury and neuroprotection hypotheses.

Topical / ocular

12

Skin repair, scarring, dry eye and corneal/neurotrophic keratopathy research, largely involving full-length Tβ4.

Reasons people report using it; these do not establish benefit.12

Evidence limits

View research →

Human efficacy, dose-response, long-term safety, and interactions of the fragment.1

3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Human exposure gap

FDA identified no human exposure data for the fragment.2

No FDA-approved TB-500 product; fragment identity must be distinguished from full-length Tβ4.

Molecular information

Amino-acid sequence

  1. Leu
  2. Lys
  3. Lys
  4. Thr
  5. Glu
  6. Thr
  7. Gln

7 residues · N → C15

Length7 amino acids
Molecular weight · Da889.0 Da
Formula, sequence notation & identity
Molecular formulaC38H68N10O1415
L–K–K–T–E–T–Q

N-terminal acetylation; this fragment is distinct from full-length thymosin beta-4.

Ac-LKKTETQ-OH; acetylated thymosin β4 fragment

Here TB-500 means the fragment. Some sellers use the same name for the 43-residue molecule. Acetate counterions add mass.

Pep-Pedia identity details

7 amino acids · 889.02 Da

Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

Reference description; checked chemical identity above takes precedence when available.12

Pharmacokinetics

How long does it stay in the body?

Unverified reference estimateNot independently confirmed
Reference half-life2.5 hours11
Route / formulationSource page: Injectable. Exact PK route not verified.

The TB-500 name can refer to different molecules. Full-length thymosin beta-4 data cannot establish elimination of the acetylated seven-residue fragment.

Illustrative half-life model for TB-500: Pep-Pedia estimateNormalized terminal-phase decline, not measured blood concentration or effect duration. Five half-lives leaves 3.125%. 0%50%100%02.5 h5 h7.5 h10 h12.5 h1 half-life
50%of reference level

Illustrative scenario using an unverified reference estimate.

About 3% remaining after 12.5 h

Five half-lives in this estimated model. This is not a prediction of when effects stop.

Evidence and model details

Population: Not established by the reference estimate

Source’s stated attribution: Goldstein et al.

Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.

100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Additional research

A rat metabolite remained detectable up to 72 hours; this does not mean TB-500 has a 72-hour human half-life. Metabolite wound-closure tests were cell experiments.3

Reported timelines

Reference & community

Source expectations

Inflammation 1–2 weeks; repair 2–8; strength 6–12. Ocular 1–2-week claims cannot be transferred to fragment products.12

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Primary goal

Recovery/Healing85%
General wellness6%
Muscle growth3%
Anti-aging2%
Other: Spinal stenosis1%

The source hides 2 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “860 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

  • Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
  • The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
  • Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
  • Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
  • This is a dated snapshot, not a live survey or current recommendation.
Checked 2026-10-12Poll source ↗
Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Avoid treating fragment and 43-amino-acid Tβ4 as interchangeable. Source compatibility is not demonstrated safety.

13 rows
Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
RouteDoseFrequencyGoal / evidenceDurationReferences
SubQSubcutaneous2-3 mg2x weeklyGeneral tissue repairReference report6-12 weeks12
IMIntramuscular2-3 mg2x weeklyGeneral tissue repairReference report6-12 weeks12
SubQSubQ near injury site4-5 mg3x weeklySerious injury recoveryReference report6-12 weeks12
SubQ2-3 mg2x weeklyAthletic enhancementReference report6-12 weeks12
SubQSubcutaneous3-4 mg2-3x weeklyChronic conditionsReference report6-12 weeks12
IMIntramuscular3-4 mg2-3x weeklyChronic conditionsReference report6-12 weeks12
SubQ2 mg1-2x weeklyMaintenanceReference report6-12 weeks12
SubQ3-5 mg3x weeklyPost-surgical recoveryReference report6-12 weeks12
TopicalTopical gel application0.02-0.03%2x dailyChronic wound healingReference report4-8 weeks or until healing complete12
OtherEye drops0.01%1-2x dailyDry eye treatmentReference report4-8 weeks or until healing complete12
TopicalTopical gel0.01-0.02%2x dailyAcute wound healingReference report4-8 weeks or until healing complete12
TopicalTopical application0.01%1-2x dailyPost-procedure careReference report4-8 weeks or until healing complete12
OtherEye drops (medical supervision)0.01%1-2x dailyCorneal injuriesReference report4-8 weeks or until healing complete12

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports12

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period
6-12 weeks
Break
4-6 weeks
Reported timing

Flexible timing, before or after meals

Topical

Use period
4-8 weeks or until healing complete
Break
As needed based on condition
Reported timing

Apply to clean, dry skin as directed

Side effects & safety

Human exposure gap

FDA identified no human exposure data for the fragment.

2

Immune response concern

FDA flags aggregation and impurity-related immunogenicity.

2

Identity errors

Fragment and full-length evidence cannot establish one another’s safety.

15

Additional reported cautions

Reference reports12

Unknown safety

Human fragment efficacy/safety unestablished; source flags malignancy, immunosuppressants and pregnancy/breastfeeding.

Stop symptoms

Infection, prolonged swelling/redness, allergy, systemic illness, worsening eye symptoms or vision changes.

Eyes

Research powders are not sterile ophthalmic products.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

7 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

BPC-157

Unverified pairing

Unproven recovery stack.12

Reference report · Pep-Pedia label: Synergistic

Ipamorelin

Unverified pairing

Untested pairing.12

Reference report · Pep-Pedia label: Compatible

CJC-1295

Unverified pairing

Untested pairing.12

Reference report · Pep-Pedia label: Synergistic

IGF-1

Unverified pairing

Untested growth signaling.12

Reference report · Pep-Pedia label: Synergistic

GHRP-6

Unverified pairing

Untested pairing.12

Reference report · Pep-Pedia label: Compatible

Melanotan II

Unverified pairing

Untested pairing.12

Reference report · Pep-Pedia label: Compatible

BPC-157 and other peptides

Not established

The checked sources provide no controlled human interaction study for the verified seven-residue fragment.12

Research context

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

mg

Total labeled amount of TB-500.

mL

Usable capacity of the destination vial or pen cartridge.

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents TB-500

Listed amounts are packaging examples. Check your actual label.

Reconstitution

Laboratory solubility only

A reagent insert is available; it is not an injectable-product instruction.6

Cayman item 45081

The insert reports PBS pH 7.2 solubility and recommends aqueous storage no longer than one day. It does not validate bacteriostatic-water injection or multidose use.6

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.

Solvents mentioned
Bacteriostatic water
Reported parameters
Reported post-preparation interval: 28 days. · The source specifies refrigeration after preparation.

The source describes gentle mixing and avoiding vigorous shaking.

Topical

The source describes prepared topical or ophthalmic products under product-specific instructions.

Form
Source describes a prepared product

A generic topical compound is not interchangeable with a sterile ophthalmic formulation.

12
Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite Lyophilized PowderReported appearanceClear Solution After ReconstitutionReported appearanceProper Vacuum SealReported variationSlight Powder ClumpingReported concernColored or Crystalline PowderReported concernPersistent Cloudiness
12

Vial sizes

5mg5
10mg5

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Injectable

Unverified report12
28 days2–6°C
Full storage notes from Pep-Pedia12
Injectable

Fridge 2-6°C, use within 28 days

Topical

Room temperature, protect from light

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements Scales, capacity & references

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗
V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment
1 unit
Cartridge capacity
3 mL
Maximum setting
60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units
0.10 mL
30-unit capacity
0.30 mL
50 / 100-unit capacity
0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL
10 µL
0.10 mL
100 µL
Amount
mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device referencesAVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Research findings

Preclinical

Source context

Avoid treating fragment and 43-amino-acid Tβ4 as interchangeable. Source compatibility is not demonstrated safety.

Compound identity & other names

TB-500 can mean the seven-residue thymosin beta-4 fragment Ac-LKKTETQ, while some sellers use the same name for full-length thymosin beta-4. This profile covers the fragment. Evidence for full-length eye drops cannot establish fragment-injection benefits.

Other names: TB500 · TB 500 · Ac-LKKTETQ · Thymosin beta-4 fragment · Tβ4 fragment 17–23

No FDA-approved TB-500 product; fragment identity must be distinguished from full-length Tβ4.

How it may work

The reference extrapolates actin-related migration and repair mechanisms from Tβ4.12

Analytical identification of TB-500

A 2012 horse study detected N-acetylated LKKTETQ and metabolites after TB-500 administration. It established an anti-doping detection method; it did not test healing efficacy in people.

1

No human fragment evidence identified by FDA

FDA reports no identified human exposure data for drug products containing this fragment. Full-length thymosin beta-4 trials answer a different question.

2

Simultaneous quantification of TB-500 and metabolites in in-vitro experiments and rats

A rat metabolite remained detectable up to 72 hours; this does not mean TB-500 has a 72-hour human half-life. Metabolite wound-closure tests were cell experiments.

3
Research areas and evidence gaps

Fragment research. Analytical research verified the acetylated seven-residue fragment in a veterinary product.1

  • Human efficacy, dose-response, long-term safety, and interactions of the fragment.
  • Whether a product labeled TB-500 contains the fragment or the full protein.
Community reports Unvalidated

Pep-Pedia discusses tissue-repair schedules under the TB-500 label. Its terminology and the wider market can mix fragment and full-length products.4

No verified identity, comparator, or representative outcome dataset establishes these schedules. They must not be transferred between molecular forms.

Search coverage and review status

Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.

Checked
2026-10-12
Search
TB-500 LKKTETQ 2025 2026 study
Catalog
Pep-Pedia ↗ · 4 listed references retained
  • Targeted search, not a systematic or exhaustive review.
  • Retained bibliography entries marked Bibliography only have not been independently verified.
  • Distinct URLs may refer to the same publication; component and formulation boundaries remain important.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

12 sources

1TB-500 detection in equine urine and plasmaPreclinical · 2012 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

An analytical horse study identified the N-acetylated LKKTETQ fragment and metabolites. It supplies identity and detection evidence, not a human recovery outcome.

Analytical identification of TB-500

A 2012 horse study detected N-acetylated LKKTETQ and metabolites after TB-500 administration. It established an anti-doping detection method; it did not test healing efficacy in people.

Original source
2FDA: compounding safety concernsRegulator · 2026 · fda.govPrimary source checked
AI-PREPARED SUMMARY

FDA identifies TB-500 as LKKTETQ and reports absent human exposure data for the fragment.

No human fragment evidence identified by FDA

FDA reports no identified human exposure data for drug products containing this fragment. Full-length thymosin beta-4 trials answer a different question.

Original source
3Simultaneous quantification of TB-500 and metabolites in in-vitro experiments and ratsPreclinical · 2024 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

An analytical study examined TB-500 breakdown in serum/enzyme systems and rats, identifying metabolites. Rat detectability is not human elimination half-life.

Simultaneous quantification of TB-500 and metabolites in in-vitro experiments and rats

A rat metabolite remained detectable up to 72 hours; this does not mean TB-500 has a 72-hour human half-life. Metabolite wound-closure tests were cell experiments.

Additional research · Checked 2026-10-12

Original source
4Pep-Pedia: tb-500 community protocol referenceCommunity · 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

A secondary source describing popular loading and maintenance schedules; not proof of safety or efficacy.

Original source
5Cayman Chemical TB-500 acetate, item 45081Catalog · 2026 · caymanchem.comCatalog checked
AI-PREPARED SUMMARY

The catalog specifies Ac-LKKTETQ-OH, formula weight 889.0, and 5 mg / 10 mg / 25 mg quantities. Research material, not for human use.

Original source
6Cayman TB-500 acetate laboratory insertCatalog · 2026 · cdn.caymanchem.comCatalog checked
AI-PREPARED SUMMARY

Specifies Ac-LKKTETQ-OH acetate, laboratory solubility and brief aqueous-storage guidance; explicitly a research reagent.

Original source
7Cardiac Tissue Regeneration (2016)Bibliography · 2016 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The cited cardiac concept involves thymosin-beta-4-treated transplanted cells; it does not establish direct TB-500 injection benefit.

Reported population / model
Human Clinical Trial

Reported study details
IV administration · Improved cardiac function

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
8Muscle Fiber Regeneration (2015)Bibliography · 2015 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Muscle-repair claims come from dystrophin-deficient mice; identity of full thymosin beta-4 versus the TB-500 fragment needs confirmation.

Reported population / model
Mouse Model

Reported study details
6 months · Enhanced skeletal muscle repair

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
9Corneal Healing Research (2014)Bibliography · 2014 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The eye-drop evidence concerns a topical thymosin-beta-4 formulation; it cannot validate an injectable TB-500 fragment.

Reported population / model
Human Phase 2

Reported study details
Eye drops · Improved dry eye symptoms

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
10Dermal Wound Healing Study (2012)Bibliography · 2012 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Topical thymosin-beta-4 wound studies are distinct from systemic TB-500 injections and cannot establish their clinical effects.

Reported population / model
Human Phase 2

Reported study details
Topical application · Accelerated healing rate

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
11Pep-Pedia: TB-500 — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Lists a half-life of 2.5 hrs and a peak time of 30 min. Stated attribution: Goldstein et al.. The TB-500 name can refer to different molecules. Full-length thymosin beta-4 data cannot establish elimination of the acetylated seven-residue fragment. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source
12Pep-Pedia: TB-500 — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source
Source details

Related profiles

BPC-157 ↗GLOW ↗KLOW ↗Thymosin beta-4 ↗